Rising Prevalence of Target Disorders Drives Fluorescence In-Situ Hybridization (FISH) Imaging Systems Market Growth
FISH is a powerful molecular cytogenetic technique that allows the visualization and localization of specific DNA sequences within cells or tissues. This technology has revolutionized the field of genetics and diagnostics, providing researchers and clinicians with valuable insights into genetic abnormalities, chromosomal rearrangements, and various diseases. The growing prevalence of target disorders such as genetic syndromes, cancer, and other genetic anomalies drives the demand for FISH imaging systems. According to the National Library of Medicine, the US will record 1.96 million new cancer cases and 609,820 cancer deaths in 2023. The demand for accurate and reliable diagnostic tools surges with the continued rise in the prevalence of these target disorders. FISH imaging systems provide high-resolution images to aid the detection of subtle genetic changes, enabling early disease diagnosis and personalized treatment approaches. These disorders often involve genetic mutations or variations that can be accurately identified and characterized using FISH imaging systems. The ability to precisely map the location of specific genes or DNA sequences within cells has proven crucial for understanding disease mechanisms, developing targeted therapies, and making informed clinical decisions.
A prominent advantage of FISH is its ability to work with various sample types, including formalin-fixed paraffin-embedded tissues, cytological preparations, and fresh tissues. This versatility has made FISH an essential tool in both research and clinical settings, allowing the identification of genetic markers associated with diseases such as leukemia, lymphoma, solid tumors, and congenital disorders.
Fluorescence In-Situ Hybridization (FISH) Imaging Systems Market: Segmental Overview
Based on product, the market is segmented into instruments, consumables, accessories, and software. The consumables segment held the largest market share in 2022 and is anticipated to register the highest CAGR during 2022–2030. Based on application, the fluorescence in-situ hybridization (FISH) imaging systems market is segmented into cancer diagnosis, genetic disease diagnosis, infectious disease diagnosis, and others. The cancer diagnosis segment held the largest market share in 2022 and is anticipated to register the highest CAGR from 2022 to 2030. Based on end user, the market is segmented into diagnostic laboratories, contract research organizations, pharmaceutical and biotechnological companies, and others. The diagnostic laboratories segment held the larger market share in 2022 and is anticipated to register the highest CAGR during 2022–2030.
Fluorescence In-Situ Hybridization (FISH) Imaging Systems Market: Competitive Landscape and Key Developments
Euroclone SpA, TissueGnostics GmbH, Agilent Technologies Inc, Abnova Taiwan Corp, BioGenex Laboratories Inc, Leica Biosystems Nussloch GmbH, MetaSystems Probes GmbH, Bio-View Ltd, Thermo Fisher Scientific Inc, Applied Spectral Imaging, and PerkinElmer Inc are a few key companies operating in the fluorescence in-situ hybridization (FISH) imaging systems market. These companies adopt product innovation strategies to meet evolving customer demands, which allows them to maintain their brand name in the fluorescence in-situ hybridization (FISH) imaging systems market.
A few of the recent developments in the global fluorescence in-situ hybridization (FISH) imaging systems market are mentioned below:
- In August 2023 Agilent Technologies Inc. opened a new full-scale integrated biology center located at Monash University in Malaysia. It is focused on building local capabilities to accelerate research and development in the field of science.
- In June 2023, Agilent Technologies Inc had released the enhanced xCELLigence RTCA Software Pro Version 2.8, an integrated software package for running and analyzing real-time cell analysis data. This improved version enabled Agilent xCELLigence Real-Time Cell Analysis systems in GMP-regulated facilities.
- In April 2021, Applied Spectral Imaging (ASI) and KromaTiD Inc had entered a strategic commercial partnership, allowed ASI worldwide rights to market KromaTiD’s proprietary Pinpoint FISH (PPF) probes and assay services.